Pharmacological properties of GABAA receptors in rat hypothalamic neurons expressing the epsilon-subunit.
The pharmacological properties and functional role of native GABA(A) receptors (GABA(A)Rs) were investigated in rat hypothalamic neurons expressing the epsilon-subunit with the help of whole-cell patch-clamp recording and single-cell reverse transcription-PCR. Two cell groups were identified: histaminergic tuberomamillary and orexinergic/hypocretinergic neurons. Approximately 25% of histaminergic and 70% of orexinergic neurons contained mRNA encoding for the epsilon-subunit. Double-immunofluorescence staining revealed a somatic localization of this protein in these two neuronal groups. Constitutive activity, diazepam modulation, fast desensitization of maximal currents, and activation by propofol (6-98 microm) of GABA(A)Rs did not correlate with epsilon-subunit expression. Propofol at 3-12 microm potentiated GABA-mediated currents similarly in all neurons. However, noise variance analysis of GABA-mediated currents enhanced by propofol revealed a significant difference between epsilon-positive and epsilon-negative neurons. The former displayed no difference between control and potentiated responses, and, in the latter, noise was decreased in the presence of propofol. Spontaneous IPSCs recorded in cultured hypothalamic neurons were prolonged in the presence of propofol in all epsilon-negative neurons, whereas propofol-resistant IPSCs were recorded in epsilon-positive cells. The infrequent expression of the epsilon-subunit may be a key factor in the recently discovered central role of the tuberomamillary nucleus in anesthesia.
Sergeeva
Olga A
OA
Department of Neurophysiology, Heinrich-Heine-Universität, D-40001 Düsseldorf, Germany. olga.sergeeva@uni-duesseldorf.de
Andreeva
Nadja
N
Garret
Maurice
M
Scherer
Annette
A
Haas
Helmut L
HL
D018686:Anesthetics, Intravenous / Q000037:antagonists & inhibitors / Q000494:pharmacology; D000818:Animals; D001640:Bicuculline / Q000494:pharmacology; D002478:Cells, Cultured; D003975:Diazepam / Q000494:pharmacology; D004594:Electrophysiology; D005455:Fluorescent Antibody Technique; D007026:Hypothalamic Area, Lateral / Q000378:metabolism; D007031:Hypothalamus / Q000166:cytology / Q000187:drug effects / Q000378:metabolism*; D047908:Intracellular Signaling Peptides and Proteins / Q000032:analysis; D008297:Male; D009474:Neurons / Q000187:drug effects / Q000378:metabolism*; D009479:Neuropeptides / Q000032:analysis; D064446:Orexin Receptors; D000068797:Orexins; D015742:Propofol / Q000037:antagonists & inhibitors / Q000494:pharmacology; D011724:Pyridazines / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D043562:Receptors, G-Protein-Coupled; D011963:Receptors, GABA-A / Q000032:analysis / Q000187:drug effects / Q000502:physiology*; D018013:Receptors, Neuropeptide; D005680:gamma-Aminobutyric Acid / Q000494:pharmacology
D018686:Anesthetics, Intravenous; C546278:Gabre protein, rat; D047908:Intracellular Signaling Peptides and Proteins; D009479:Neuropeptides; D064446:Orexin Receptors; D000068797:Orexins; D011724:Pyridazines; D043562:Receptors, G-Protein-Coupled; D011963:Receptors, GABA-A; D018013:Receptors, Neuropeptide; D005680:gamma-Aminobutyric Acid; C049853:gabazine; D003975:Diazepam; D001640:Bicuculline; D015742:Propofol